Dentsply to exit medical imaging by selling Gendex and Eureka units
Varian signs deal to buy Eureka X-Ray assets Dentsply International said this month that it plans to divestits medical operations in a move to concentrate on its core dentalbusiness. The company has put x-ray vendor Gendex Medical,
Varian signs deal to buy Eureka X-Ray assets
Dentsply International said this month that it plans to divestits medical operations in a move to concentrate on its core dentalbusiness. The company has put x-ray vendor Gendex Medical, tubemanufacturer Eureka X-Ray Tube and orthopedic bone cement developerCMW on the block.
Shortly after the announcement, Varian Associates of Palo Alto,CA, said that it had signed an agreement to acquire the assetsof Eureka, which is based in Arlington Heights, IL. Dentsply,of Des Plaines, IL, has not yet announced an agreement to sellGendex.
The divestiture caps two years of frenzied merger and acquisitionactivity on the part of Gendex and Dentsply. Gendex purchasedEureka X-Ray Tube from Siemens in September 1992 and a few monthslater announced a plan to merge with Dentsply (SCAN 9/23/92 and2/10/93). In January 1993 Gendex bought the mammography line ofFinnish vendor Soredex.
The divestiture does not represent a retreat for Dentsply,according to Edwin J. McDonough, former Gendex president. Thecompany is planning to focus its resources on its dental businessand will use proceeds from the sale to reduce debt. McDonoughis purchasing Eureka's collimator and high-voltage cable businessand plans to run it as a separate company.
In buying Eureka's Arlington Heights facility, Varian is addinga line of low-end x-ray tubes to its existing high-end tube line,according to Robert Kluge, Varian vice president and general managerof x-ray tube products. Eureka and Varian already share many ofthe same OEM customers but manufacture tubes at different pricepoints, so the acquisition should be a good fit, he said.
Varian plans to run the Arlington Heights facility as a manufacturingplant as opposed to a separate business, and the Eureka name willmost likely be retired. Varian will probably retain most of theworkers at the facility. The facility had annual sales of about$20 million, compared to about $100 million in Varian's x-raytube business, Kluge said.
The Eureka purchase is part of Varian's strategy to expandits presence in the medical industry, according to Kluge. Varianformed a Health Care Systems group to spearhead the drive (SCAN3/2/94 and 3/24/93).
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
